KRAS and neoplasm: In these models, the pancreas-specific expression of oncogenic KRAS is combined with the loss of a tumor suppressor to drive the formation of pancreatic intraepithelial neoplasia (PanIN) lesions and their progression to PC [7,8,9,10,11].